Genmab A/S (NASDAQ:GMAB) PT Raised to $47.00 at BTIG Research

Genmab A/S (NASDAQ:GMAB) had its price target lifted by equities researchers at BTIG Research from $46.00 to $47.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price suggests a potential upside of 87.03% from the company’s current price.

Several other equities research analysts have also issued reports on GMAB. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, Truist Financial raised their price objective on Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, June 4th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Genmab A/S presently has an average rating of “Hold” and a consensus price target of $49.50.

Genmab A/S Stock Down 1.8 %

Shares of GMAB opened at $25.13 on Thursday. The business has a 50-day simple moving average of $27.96 and a two-hundred day simple moving average of $29.11. The stock has a market cap of $16.62 billion, a price-to-earnings ratio of 20.94, a PEG ratio of 0.93 and a beta of 0.99. Genmab A/S has a 52 week low of $24.94 and a 52 week high of $42.72.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. The business had revenue of $603.30 million during the quarter, compared to analysts’ expectations of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. On average, equities analysts anticipate that Genmab A/S will post 1.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of GMAB. Capital International Investors increased its holdings in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after purchasing an additional 315,355 shares during the period. Northern Trust Corp increased its holdings in Genmab A/S by 83.3% during the 3rd quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock worth $19,717,000 after purchasing an additional 254,042 shares during the period. Royal London Asset Management Ltd. purchased a new position in Genmab A/S during the 3rd quarter worth $8,939,000. Schonfeld Strategic Advisors LLC purchased a new position in Genmab A/S during the 3rd quarter worth $7,999,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Genmab A/S during the 4th quarter valued at $5,912,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.